Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON, Feb. 25 ...
American journalist Tucker Carlson called on the world to investigate the crimes of Vladimir Zelensky, whom he considers ...
Virax Biolabs has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary ...
LONDON - Virax Biolabs Group Limited (NASDAQ ... is positioning itself as a key player in the United States' push for transparency in vaccine efficacy. According to InvestingPro analysis, the ...
NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for ...
In the intricate web of global politics, Trump’s administration is taking decisive steps to resolve the ongoing ...
IPSWICH, Mass., March 5, 2025 /PRNewswire/ -- Named in honor of the founder and first Chief Executive Officer of New England Biolabs (NEB ®), Donald Comb, this annual lectureship honors those who ...
LONDON - Virax Biolabs Group Limited (NASDAQ: VRAX), a biotechnology company specializing in immune response detection and viral disease diagnosis with a market capitalization of $8.27 million, is ...
Virax Biolabs is positioned to advance vaccine transparency in collaboration with companies developing vaccines. Our cutting-edge technology enables us to provide research-based tools to measure ...
Virax Biolabs is positioned to advance vaccine transparency in collaboration with companies developing vaccines. Our cutting-edge technology enables us to provide research-based tools to measure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results